Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

ABSTRACT: Background:The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which can eradicate the cancer. Methods:We used www.cbioportal.org to determine the frequency of ERBB mutations in solid tumors. We then determined the sensitivity of a panel of cell lines to clinically available PI3K inhibitors. Using proliferation and apoptosis assays as well as functional interrogation with reverse phase protein arrays we demonstrated the impact of targeting ERBB-mutant cancers with the combination of a PI3K inhibitor and the pan-HER family inhibitor afatinib. Results:In over 14,000 patien

SUBMITTER: Milewska M 

PROVIDER: S-EPMC5784557 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature